Bicycle Therapeutics plc announced that Travis Thompson will take over as chief financial officer, succeeding Alethia Young. Michael Method, M.D., MPH, MBA, has been promoted to chief medical officer, replacing Eric Westin, M.D. Michael Skynner, Ph.D., formerly the chief technology officer, will transition to chief scientific officer.
Alethia Young will serve as interim CFO through April 29, 2026, after which she will become an advisor to the board. Eric Westin has retired from the CMO role and will continue as a distinguished fellow, while Skynner’s move to CSO positions him to lead the company’s scientific strategy across its pipeline.
The appointments are part of Bicycle’s effort to strengthen operational capacity and extend its financial runway into 2028. The company is advancing a portfolio of oncology candidates built on its proprietary Bicycle molecule platform, including multiple Phase III studies and candidates such as zelenectide pevedotin, BT5528 and BT7480.
CEO Kevin Lee said the new leadership team, together with the board and advisors, will drive momentum across the oncology pipeline and support the company’s goal of delivering shareholder value. He added that the appointments signal a strategic shift toward deeper scientific and financial stewardship as the company moves into a critical execution phase.
With Thompson’s financial expertise, Method’s clinical development experience, and Skynner’s scientific leadership, Bicycle is positioned to navigate the complex regulatory and commercial landscape of oncology. The extended runway gives the company time to bring its Bicycle molecules to market, pursue radiopharmaceutical partnerships, and capitalize on the growing demand for targeted cancer therapies.
These leadership changes underscore Bicycle’s commitment to executing its long‑term strategy and reinforce confidence in its ability to deliver on its oncology pipeline objectives.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.